Abbott Laboratories Corporation

Anne C Voss

Pradip Mukerji

Jeffrey H Baxter

Michael John Tisdale

Michael J Tisdale

Refaat A Hegazi

Maria G Baggs

Fabrizis Suarez

Jeffrey L Nelson

Charles L Paule

Gary Fanjiang

Disclosed is the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for use in a method of treating a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. 9. Also disclosed is the use of the combination of beta-hydroxy-beta-methylbutryate, arginine, and glutamine for the manufacture of a medicament for use in the treatment of a diabetic ulcer in a diabetic individual having at least one of: (a) a serum albumin level of less than or equal to 4.0 g/dL, and/or (b) an Ankle-Brachial Index of less than 1.0. In certain embodiments, the combination of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine are orally administered via a nutritional composition.

Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 &#x3c9;-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and substantially lacking in free amino acids.

Compositions including beta-hydroxy-beta-methylbutyrate

Method of using beta-hydroxy-beta-methylbutyrate for treating disease-associated wasting

Method of using &#x3b2;-hydroxy-&#x3b2;-methylbutyrate for the treatment of disease conditions

The present invention relates to methods for the prevention and treatment of chronic inflammatory diseases, cancer, and involuntary weight loss. In the practice of the present invention patients are enterally administered HMB alone or alternatively in combination with eicosapentaenoic (20:5 &#x3c9;-3), FOS, carnitine and mixtures thereof. HMB may be added to food products comprising a source of amino-nitrogen enriched with large neutral amino acids such as leucine, isoleucine, valine, tyrosine, threonine and phenylalanine and subtantially lacking in free amino acids.

Method of using beta-hydroxy-beta-methylbutyrate and fatty acids for treating disease-associated wasting

Method of using beta-hydroxy-beta-methylbutyrate for reducing tumor growth rate

HMB uses thereof

Growing community of inventors

Columbus, OH, United States of America

Anne C Voss